Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N07XX16

Austedo(deutetrabenazine)

Tardive Dyskinesia

Marketing Authorisation Holder: Teva GmbH

EMA Authorisation: 08/01/2026

INN: deutetrabenazine

Indication

Treatment of moderate to severe tardive dyskinesia in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Austedo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.